Erectile dysfunction and its treatment – pharmacological and clinical profile of avanafil
Authors:
T. Šrámková
Published in the journal:
Urol List 2014; 12(2): 65-67
Summary
Modern ED therapy, which in the first line consists of PDE5 inhibitors (PDE5-I) application, is safe and effective and is well tolerated. Avanafil, a new agents, is a highly potent PDE5 inhibitor and highly selective for PDE5. Results of phase III clinical trials suggest that avanafil is an effective and well tolerated treatment for ED of broad-spectrum aetiology and severity. The improvement in sexual function and tolerability coupled with the rapid onset of action and durability of effect make avanafil a viable tool for on demand treatment of ED.
Key words:
erectile dysfunction, treatment, phosphodiesterase 5 inhibitors, avanafil
Zdroje
1. Weiss P, Zvěřina J. Sexuální chování v ČR – situace a trendy. 1. ed. Praha: Portál 2001.
2. Šrámková T. Poruchy sexuality u somaticky nemocných a jejich léčba. Praha: Grada Publishing 2013.
3. Wespes E, Eardley I, Giuliano F et al. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Guidelines EAU 2013. Available from: http:/ / www.uroweb.org/ gls/ pdf/ 14_Male%20Sexual%20Dysfunction_LR.pdf.
4. Státní ústav pro kontrolu léčiv. SmPC sildenafil, tadalafil, vardenafil 2013. [online]. Dostupné z: www.sukl.cz/ modules/ medication.
5. Salonia A, Burnett AL, Graefen M et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol 2012; 62(2): 261– 272. doi: 10.1016/ j.eururo.2012.04.046.
6. Státní ústav pro kontrolu léčiv. SmPC avanafil 2013. [online]. Dostupné z: www.sukl.cz/ modules/ medication.
7. Goldstein I, McCullough AR, Jones LA et al. A randomized, double‑blind, placebo– controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9(4): 1122– 1133. doi: 10.1111/ j.1743‑ 6109.2011.02629.x.
8. Goldstein I, Jones LA, Belkoff LH et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double‑blind study in men with diabetes mellitus. Mayo Clin Proc 2012; 87(9): 843– 852. doi: 10.1016/ j.mayocp.2012.06.016.
9. Mulhall JP, Moul JW, Wang R et al. A phase III, placebo- controlled study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral nerve– sparing radical prostatectomy. J Sex Med 2012; 9: S42– S43.
10. Belkoff LH, McCullough A, Goldstein I et al. An open- label, long‑term evaluation of the safety, efficacy and tolerability of avanafil in male patiens with mild to severe erectile dysfunction. Int J Clin Pract 2013; 67(4): 333– 341. doi: 10.1111/ ijcp.12065.
11. Alwaal A, Al- Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther 2011; 5: 435– 443. doi: 10.2147/ DDDT.S15852.
12. Vyhnánková V, Pacík D, Čermák A. Vývoj medikamentózní terapie ED – minulost, současnost, budoucnost. Urol List 2014; 12(1): 19– 23.
Štítky
Paediatric urologist UrologyČlánok vyšiel v časopise
Urological Journal
2014 Číslo 2
Najčítanejšie v tomto čísle
- Active approach to prostate cancer detection – what is reasonable and what may cause harm
- Prostate cancer – from hormonal dependency to castration resistant cancer
- Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer
- Erectile dysfunction and its treatment – pharmacological and clinical profile of avanafil